NCT02558907

Brief Summary

Compare neurocognitive testing MMSE (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) to candidates aged patients with 1st line treatment of their cancer will be received an examination oncogériatric

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
66

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Sep 2015

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2015

Completed
17 days until next milestone

First Submitted

Initial submission to the registry

September 18, 2015

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 24, 2015

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2017

Completed
Last Updated

April 4, 2017

Status Verified

June 1, 2016

Enrollment Period

1.5 years

First QC Date

September 18, 2015

Last Update Submit

March 31, 2017

Conditions

GeriatricsCancer

Keywords

geriatricscancerMMS testMoCA testcognitive evaluation

Outcome Measures

Primary Outcomes (1)

  • proportion of patients with cognitive disorders identified by the MoCA or the MMSE prior to treatment

    before their first treatment for the cancer, at inclusion

Interventions

cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) testsOTHER

Eligibility Criteria

Age71 Years+
Sexall
Healthy VolunteersNo
Age GroupsOlder Adult (65+)
Sampling MethodProbability Sample
Study Population

aged patients with 1st line treatment of their cancer will be received an examination oncogériatric

You may qualify if:

  • Patient old over 70 years
  • Patient with cancer (solid tumor or hematological) for which a 1st line treatment is planned
  • Patient candidate an oncogeriatric assessment
  • Patient agreeing to participate in the study
  • French language
  • Lack of subsequent neurological sequelae with cognitive impact stroke, dementia or progressive psychiatric disorder
  • Patient having a life expectancy ≥ 6 months

You may not qualify if:

  • Primitive cancer of the central nervous system or brain metastasis
  • Patients unable to meet the cognitive tests
  • Refusal to participate
  • Realization of a MMSE or MoCA test in the last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU

Caen, 14033, France

Location

Centre François Baclesse

Caen, France

Location

MeSH Terms

Conditions

Neoplasms

Interventions

Mental Status and Dementia Tests

Intervention Hierarchy (Ancestors)

Neuropsychological TestsPsychological TestsBehavioral Disciplines and Activities

Study Officials

  • Heidi LAVIEC, MD

    Centre François Baclesse - CAEN

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2015

First Posted

September 24, 2015

Study Start

September 1, 2015

Primary Completion

March 1, 2017

Study Completion

March 1, 2017

Last Updated

April 4, 2017

Record last verified: 2016-06

Locations

FR(2)